Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss
NCT02954627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2019-03-25
Summary
This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.
This substudy aims to investigate any changes in the carotid intima media thickness (CIMT) assessed by ultrasound in relation to an initial 8-week weight loss intervention.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Dietary Supplement: Intensive dietary intervention
Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Sponsors & Collaborators
-
Henrik Gudbergsen
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 74 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-30
- Primary Completion
- 2019-02-28
- Completion
- 2019-03-31
Countries
- Denmark
Study Locations
More Related Trials
-
Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance
NCT02928614 ·Status: COMPLETED ·Phase: PHASE4
-
Weight Loss and Physical Activity in Overweight/Obese Individuals With Knee Osteoarthritis
NCT02910544 ·Status: COMPLETED
-
Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis
NCT02910570 ·Status: COMPLETED ·Phase: PHASE4
-
Liraglutide 3 mg for Knee Osteoarthritis
NCT02905864 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Liraglutide 3.0 on Body Fat Distribution
NCT03038620 ·Status: COMPLETED ·Phase: PHASE4
-
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
NCT05419726 ·Status: RECRUITING
-
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT02963922 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
NCT06501326 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
NCT01508949 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
NCT03523273 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
NCT02717858 ·Status: COMPLETED ·Phase: PHASE1
-
Liraglutide to Improve corONary Haemodynamics During Exercise streSS
NCT02315001 ·Status: COMPLETED ·Phase: PHASE2
-
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
NCT02963935 ·Status: COMPLETED ·Phase: PHASE3
-
Effect Of Semaglutide In Coronary Atheroma Plaque
NCT05071417 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Liraglutide and Cardio-Metabolic Risk Markers
NCT01715428 ·Status: COMPLETED
-
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548 ·Status: COMPLETED ·Phase: PHASE3
-
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548987 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
NCT04605861 ·Status: COMPLETED ·Phase: PHASE3
-
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
NCT01784965 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367 ·Status: COMPLETED ·Phase: PHASE3
-
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
NCT03856047 ·Status: COMPLETED ·Phase: PHASE2
-
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
NCT05064735 ·Status: COMPLETED ·Phase: PHASE3
-
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711 ·Status: COMPLETED ·Phase: PHASE2
-
Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
NCT01237119 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities
NCT04487743 ·Status: UNKNOWN ·Phase: PHASE3